Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a single transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ADSs (Dividend Re-investment) |
| Instrument | American Depositary Shares (ADSs) ISIN: US37733W1053 |
| Transaction Date | July 18, 2016 |
| Price per ADS | $44.190 |
| Volume | 10.899 ADSs |
| Exchange | NYSE (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an initial notification of a transaction by Dr. M M Slaoui, Chairman of Global Vaccines, involving the acquisition of 10.899 ADSs following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine disclosure of an insider transaction.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. M M Slaoui, Chairman of Global Vaccines.
- Transaction Nature: The purchase was not a direct cash buy but an acquisition resulting from the re-investment of dividends.
- Transaction Size: The volume was minimal (10.899 ADSs), indicating a standard dividend reinvestment plan (DRIP) activity rather than a significant strategic position change.
- Market Price: The transaction occurred at a price of $44.190 per ADS on the NYSE.